clinical trial · NCT06363760
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
Editas Medicine, Inc.·—·enrolling by invitation·n = 54
Sickle Cell DiseaseTransfusion-dependent Beta-ThalassemiaHemoglobinopathiesSafety and efficacy assessments
brief summary
The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.
started
Jun 17, 2024
primary completion
Aug 1, 2040
completion
Aug 1, 2040
last updated
Apr 2, 2025
detailed description
This is a non-interventional, multicenter study evaluating the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion dependent b-thalassemia (TDT) who received EDIT-301 in parent studies EM-SCD-301-001 (NCT04853576) or EDIT-301-BThal-001 (NCT05444894). No investigational drug product will be administered in the LTFU study.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol